Caleb Tripp

Saiers Capital operates global multi-strategy investment funds that currently focus on volatility arbitrage, while employing other arbitrage strategies (such as risk arbitrage, convertible bond arbitrage, capital structure arbitrage) and directional strategies. The funds are authorized to invest, directly or indirectly, in all types of securities and instruments, both US and non-US, and to participate in other potentially profitable opportunities, including the short selling of securities. Examples of securities traded and other investments made include listed and over-the-counter options, equity and debt securities and listed and over the counter derivatives, ETFs, futures, variance swaps, correlation swaps, equity swaps, credit default swaps, foreign exchange and commodities. Saiers Capital's investment strategies include: (1) volatility arbitrage (2) long and short investments (3) fixed-income securities and derivatives (4) commodity securities and derivatives (5) futures contracts and other derivatives (6) foreign exchange/foreign currency (7) PIPEs (8) special situations and risk arbitrage (9) capital structure arbitrage. In addition, the firm may invest some of their clients' assets in short-term US Government obligations, certificates of deposit (including sovereign and corporate), commercial paper and other money market instruments to enable the clients to make investments quickly and to serve as collateral with respect to certain investments.

DW seeks high absolute returns from niche strategies within the real estate debt universe. The firm buys bonds and originates loans in strategies where it has a portfolio manager and team with extensive experience in the underlying investments through various cycles. While they trade heavily in US markets, DW may also trade globally, typically concentrating in developed markets.

Functions as a College/University

Functions as a College/University

Provides web-based financial products

Cormorant Asset Management/Private Equity/ invests in companies located in the United States. The firm targets companies operating in the fields of life-science and biotech. It provides financing for mezzanine and early stage capital requirements.